This site is intended for U.S. healthcare professionals.

Our Purpose

To provide up-to-date clinical trial and Real World Evidence from peer-reviewed publications for the Pfizer-BioNTech COVID-19 Vaccine using interactive data visualization of results and objective key summaries for vaccine-related topics. Learn More

View Vaccine & COVID-19 related Topics

Click on a topic below to view

Has taxonomy term

XBB-adapted COVID-19 Vaccine Medical Rationale - Select Considerations
Original Monovalent and Bivalent BNT162b2 COVID-19 Vaccine Data:
Clinical Trials
Vaccine Efficacy
Vaccine Safety
Real World Evidence
Vaccine Effectiveness
General Population
Omicron Era
Adults
Primary Series (monovalent)
Boosters
Monovalent
Bivalent
Pediatrics
Primary series (monovalent)
Boosters
Monovalent
Bivalent(coming soon)
Omicron Preprints
Pre-Omicron era
Adults
Primary series (monovalent)
Boosters (monovalent)
Pediatrics
Primary series (monovalent)
Special Populations
Pregnant Women
Immunocompromised
Geriatrics
Vaccine Safety
Vaccine-Associated Myo/pericarditis

Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Previous COVID-19 vaccines, including original monovalent COVID-19 vaccines and bivalent (original and Omicron BA.4/BA.5) mRNA COVID-19 vaccines, are no longer authorized for use in the United States. FDA and CDC guidance is to check inventory and dispose of previous COVID-19 vaccines according to state and local regulations.

Welcome to Pfizer-BioNTech COVID-19 Vaccines Medical Data

No cost, No sign-up required
Updated with peer-reviewed literature on COVID-19
Focus on the Pfizer-BioNTech COVID-19 Vaccine
Interactive
Key Point summaries to help understand medical data

This site is intended for US Healthcare Professionals. By selecting continue below, you acknowledge and certify that you are a US Healthcare Professional.

Emergency uses of the Pfizer-BioNTech COVID-19 Vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.